News - Page 70 - Psychedelic Alpha

Our 🎯 Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.

Read more about the article <strong>Australia Recognises MDMA and Psilocybin as Medicines</strong>

Australia Recognises MDMA and Psilocybin as Medicines

Post published:February 3, 2023
Post category:Analysis

Read more about the article A Perspective from the ‘Reimagining Psychedelic Trials’ Working Group

A Perspective from the ‘Reimagining Psychedelic Trials’ Working Group

Post published:February 2, 2023
Post category:2022 Year in Review

Read more about the article Historical Insights on the Psychedelic Renaissance

Historical Insights on the Psychedelic Renaissance

Post published:February 2, 2023
Post category:2022 Year in Review

Read more about the article A Spotlight on Psychedelic Research Methods

A Spotlight on Psychedelic Research Methods

Post published:February 2, 2023
Post category:2022 Year in Review

Read more about the article Panel: Psychedelic Research Methods

Panel: Psychedelic Research Methods

Post published:February 2, 2023
Post category:2022 Year in Review

Read more about the article PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX™ (Ketamine) for the Treatment of Rett Syndrome

PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX™ (Ketamine) for the Treatment of Rett Syndrome

Post published:February 2, 2023
Post category:Press Release

Read more about the article Silo Pharma Announces Expansion of Intellectual Property Portfolio

Silo Pharma Announces Expansion of Intellectual Property Portfolio

Post published:February 2, 2023
Post category:Press Release

Read more about the article Ehave Provides Progress Update on its HPPD Study with University of Melbourne

Ehave Provides Progress Update on its HPPD Study with University of Melbourne

Post published:February 2, 2023
Post category:Press Release

Read more about the article Reunion Neuroscience Schedules Fiscal Third Quarter 2023 Conference Call for Tuesday, February 14, 2023, at 8:30 A.M. ET

Reunion Neuroscience Schedules Fiscal Third Quarter 2023 Conference Call for Tuesday, February 14, 2023, at 8:30 A.M. ET

Post published:February 2, 2023
Post category:Press Release

Read more about the article Mindset Pharma Receives Another Allowance from USPTO for Patent Application Expanding Composition of Matter for Family 1 Psilocybin Analogs

Mindset Pharma Receives Another Allowance from USPTO for Patent Application Expanding Composition of Matter for Family 1 Psilocybin Analogs

Post published:February 2, 2023
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.